A new blue
Heinrich Caro synthesises methylene blue, one of the earliest synthetic dyes used at industrial scale.
A molecule with a remarkable history
From the first synthetic dye to a clinically important medicine, explore the chemistry, established use, current research and essential safety context.
Explore the molecule ↓02 / THE STORY
Methylene blue began as a textile dye. Its ability to move between oxidised and reduced states, and to selectively stain biological material, turned it into a tool for microscopy, research and medicine.
Heinrich Caro synthesises methylene blue, one of the earliest synthetic dyes used at industrial scale.
Researchers discover that it selectively colours certain cells and microbes, making microscopic structures easier to study.
Paul Ehrlich explores it against malaria, an early example of a synthetic chemical being investigated as a medicine.
Its established modern role includes clinician-administered treatment of acquired methemoglobinemia.
03 / THE MOLECULE
Methylene blue is an oxidation-reduction agent. In simplified terms, it can accept electrons to become colourless leucomethylene blue and later donate them as it returns to its blue oxidised form.
IUPAC FAMILYPhenothiazine
APPEARANCEDeep blue crystalline solid
SOLUBILITYSoluble in water
BEHAVIOUROxidation-reduction active
Its chemistry allows it to cycle between oxidised and reduced forms. This redox behaviour underlies both its distinctive colour and its clinical action.
In acquired methemoglobinemia, clinician-administered methylene blue helps convert ferric iron in methemoglobin back toward the ferrous state used by functional haemoglobin.
The same chemistry can create risks at unsuitable doses or in certain people. Route, formulation, diagnosis, medicines and G6PD status all matter.
04 / ESTABLISHED CLINICAL USE
Prescription methylene blue injection is indicated for adults and children with acquired methemoglobinemia, a condition where altered haemoglobin cannot carry oxygen effectively.
This is a diagnosed medical condition. Treatment is intravenous and managed by healthcare professionals; it is not a template for oral self-dosing.
Methylene blue has long been used as a stain or visual marker in selected laboratory, diagnostic and surgical contexts. The exact formulation and route depend on the procedure.
A compound having a legitimate medical use does not validate unrelated wellness claims. Evidence, dose, purity, route and clinical oversight cannot be separated.
05 / RESEARCH LANDSCAPE
Methylene blue is studied across several fields. These areas describe scientific interest, not proven consumer benefits, approved wellness uses or reasons to self-medicate.
Researchers study how its redox activity interacts with mitochondrial electron transfer and oxidative stress under controlled conditions.
PRECLINICAL + EXPLORATORYMemory, neurodegeneration and brain metabolism have been explored, but findings vary by model, dose and study design.
NOT AN APPROVED COGNITIVE AIDWhen activated by certain wavelengths of light, methylene blue can generate reactive species; this is researched in antimicrobial and other specialised applications.
CONTEXT-SPECIFIC RESEARCH06 / ESSENTIAL SAFETY
Methylene blue is biologically active. It can interact with medicines, cause adverse effects and be dangerous for some people. Use for a medical purpose should be guided by a qualified healthcare professional.
Methylene blue inhibits monoamine oxidase A. Combining it with serotonergic medicines, including many antidepressants, can cause a serious, potentially life-threatening reaction. Urgent symptoms may include agitation, confusion, sweating, fever, diarrhoea, muscle rigidity or tremor.
It can cause severe breakdown of red blood cells and anaemia in people with glucose-6-phosphate dehydrogenase deficiency. Prescription injection is contraindicated in this group.
Potential fetal or infant risks require individual medical assessment. Do not use without advice from a clinician who knows your circumstances.
Higher exposure can paradoxically worsen methemoglobinemia or cause haemolysis. Clinical dosing is diagnosis- and route-specific.
Blue-green urine, stool or skin staining can occur and may interfere with pulse oximetry and some laboratory measurements.
07 / QUALITY MATTERS
Products made for laboratories, textiles, aquariums or microscopy are not manufactured for human use. Labels such as "USP" should be supported by traceable quality documentation, not treated as a safety guarantee.
01IdentityVerified compound and concentration
02PurityTested for relevant contaminants
03TraceabilityLot and manufacturing records
04SuitabilityCorrect formulation for the intended route
08 / COMMON QUESTIONS
Yes. Prescription methylene blue injection is used clinically for acquired methemoglobinemia. That does not mean every product sold as methylene blue is a medicine, suitable for ingestion, or equivalent in purity and formulation.
It is a condition in which iron in haemoglobin is oxidised into a form that cannot carry oxygen effectively. Symptoms can include headache, fatigue, shortness of breath and blue-grey skin. Severe cases are a medical emergency.
Research is active, but many claims involving energy, cognition, longevity or daily supplementation are not established approved uses. Laboratory findings, animal research and early human studies should not be presented as proof of a consumer health benefit.
Methylene blue inhibits monoamine oxidase A. Combining it with serotonergic medicines can raise serotonin to dangerous levels and cause serotonin syndrome. A clinician must review medicines and supplements before use.
It refers to a product manufactured and tested against a recognised medicine-quality standard. It does not make unsupervised use safe, and it is not the same as laboratory, industrial, staining or aquarium-grade material.
09 / SOURCE NOTES